Klinisk Biokemi i Norden Nr 2, vol. 23, 2011 - page 42

42
| 2 | 2011
Klinisk Biokemi i Norden
(
Fortsat fra side 41)
regulation of microRNA biogenesis, function
and decay. Nat Rev Genet 2010;11:597-610.
14.
Yu SL, Chen HY, Chang GC, Chen CY, Chen
HW, Singh S, et al. MicroRNA signature predicts
survival and relapse in lung cancer. Cancer Cell
2008;13:48-57.
15.
Liang Y, Ridzon D, Wong L, Chen C. Characteri-
zation of microRNA expression profiles in nor-
mal human tissues. BMCGenomics 2007;8:166.
16.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E,
Lamb J, Peck D, et al. Expression profiles classify
human cancers. Nature 2005;435:834-8.
17.
Cummins JM, Velculescu VE. Implications
of micro-RNA profiling for cancer diagnosis.
Oncogene 2006;25:6220-7.
18.
Liu CG, Calin GA, Meloon B, Gamliel N, Sevi-
gnani C, Ferracin M, et al. An oligonucleotide
microchip for genome-wide microRNA profil-
ing in human and mouse tissues. Proc Natl Acad
Sci U S A 2004;101:9740-4.
19.
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et
al. Characterization of microRNAs in serum: a
novel class of biomarkers for diagnosis of cancer
and other diseases. Cell Res 2008;18:997-1006.
20.
Simpson RJ, Lim JW, Moritz RL, Mathivanan S.
Exosomes: proteomic insights and diagnostic
potential. Expert Rev Proteomics 2009;6:267-83.
21.
Cortez MA, Calin GA. MicroRNA identification
in plasma and serum: a new tool to diagnose
and monitor diseases. Expert Opin Biol Ther
2009;9:703-11.
22.
van Rooij E, Olson EN. MicroRNAs: powerful
new regulators of heart disease and provocative
therapeutic targets. J Clin Invest 2007;117:2369-76.
23.
LatronicoMV, Condorelli G. On the road to the
definition of the cardiac miRNome in human
disease states. J Mol Cell Cardiol 2008;45:162-4.
24.
Small EM, Olson EN. Pervasive roles of
microRNAs in cardiovascular biology. Nature
2011;469:336-42.
25.
Thum T, Gross C, Fiedler J, Fischer T, Kissler S,
Bussen M, et al. MicroRNA-21 contributes to
myocardial disease by stimulating MAP kinase
signalling in fibroblasts. Nature 2008;456:980-4.
26.
Patrick DM, Montgomery RL, Qi X, Obad S,
Kauppinen S, Hill JA, et al. Stress-dependent car-
diac remodeling occurs in the absence of micro-
RNA-21 in mice. J Clin Invest 2010;120:3912-6.
27.
Morrisey EE. The magic and mystery of miR-21.
J Clin Invest 2010;120:3817-9.
28.
LaDue JS, Wroblewski F, Karmen A. Serum
glutamic oxaloacetic transaminase activity in
human acute transmural myocardial infarction.
Science 1954;120:497-9.
29.
Røsjø H, Omland T. New cardiovascular risk
markers: The race is on, but are there any win-
ners? Scand J Clin Lab Invest 2008;68:673-7.
30.
Gerszten RE, Wang TJ. The search for new cardi-
ovascular biomarkers. Nature 2008;451:949-52.
31.
Mitchell PS, Parkin RK, Kroh EM, Fritz BR,
Wyman SK, Pogosova-Agadjanyan EL, et al.
Circulating microRNAs as stable blood-based
markers for cancer detection. Proc Natl Acad
Sci U S A 2008;105:10513-8.
32.
Arroyo JD, Chevillet JR, Kroh EM, Ruf IK,
Pritchard CC, Gibson DF, et al. Argonaute2
complexes carry a population of circulating
microRNAs independent of vesicles in human
plasma. Proc Natl Acad Sci U S A: 2011: Epub
before print (doi: 10.1073/pnas.1019055108).
33.
Chitwood DH, Timmermans MC. Small RNAs
are on the move. Nature 2010;467:415-9.
34.
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et
al. Characterization of microRNAs in serum: a
novel class of biomarkers for diagnosis of cancer
and other diseases. Cell Res 2008;18:997-1006.
35.
Ji X, Takahashi R, Hiura Y, Hirokawa G, Fukush-
ima Y, Iwai N. Plasma miR-208 as a biomarker of
myocardial injury. Clin Chem 2009;55:1944-9.
36.
Tijsen AJ, Creemers EE, Moerland PD, De
Windt LJ, van der Wal AC, Kok WE, et al.
MiR423-5p as a circulating biomarker for heart
failure. Circ Res 2010;106:1035-9.
37.
Fichtlscherer S, De RS, Fox H, Schwietz T, Fis-
cher A, Liebetrau C, et al. Circulating microR-
NAs in patients with coronary artery disease.
Circ Res 2010;107:677-84.
38.
Morrow DA, de Lemos JA. Benchmarks for the
assessment of novel cardiovascular biomarkers.
Circulation 2007;115:949-52.
39.
Røsjø H, Omland T. New statistical methods for
the evaluation of cardiovascular risk markers:
what the clinician should know. Clin Sci (Lond)
2009;117:13-5.
1...,32,33,34,35,36,37,38,39,40,41 43,44,45,46,47,48,49,50,51,52,...56
Powered by FlippingBook